IBI Ag was founded and incubated by Trendlines, and its proprietary platform adapts single-domain antibody technology from human therapeutics to agriculture, enabling the development of precise, environmentally responsible bioinsecticides.
A portfolio company of The Trendlines Group has raised a $10 million series A financing round.
Trendlines Group, which is an investment group focused on agrifood and medtech innovation, has a 11.2% stake, post series A funding round, in the portfolio company IBI Ag.
